A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors

StatusUnknown
PhasePhase 1
Started

Record status This record was last updated November 8, 2023 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Changed Registry marked status Unknown (sponsor has not verified the record since Aug 2023); last known: Recruiting
  2. Start date: Sep 30, 2023 to Nov 30, 2023v2
  3. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a single-center, double-arm, open-label study. this study plans to evaluate the safety and efficacy of CD70-targeting CAR-T cells in the treatment of CD70-positive advanced/metastatic solid tumors, and obtain recommended doses and infusion patterns.
Trial Details
NCT Number NCT06010875
Lead Sponsor Chongqing Precision Biotech Co., Ltd
Collaborators: The First Affiliated Hospital of Nanchang University
Conditions
(from sponsor)		 Renal Cell Carcinoma, Ovarian Cancer, Cervix Cancer, Metastatic Cancer, Advanced Cancer
Related terms Carcinoma, Renal Cell, Neoplasm Metastasis, Ovarian Neoplasms, Uterine Cervical Neoplasms
Enrollment 48 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov